PIM Kinase As an Executional Target in Cancer

Overview

Journal J Cancer Prev

Specialty Oncology

Date 2018 Oct 30

PMID 30370255

Citations 59

Authors

Xinning Zhang

Mengqiu Song

Joydeb Kumar Kundu

Mee-Hyun Lee

Zhen-Zhen Liu

Affiliations

Soon will be listed here.

Abstract

PIM (proviral integration site for moloney murine leukemia virus) kinase plays a key role as an oncogene in various cancers including myeloma, leukemia, prostate and breast cancers. The aberrant expression and/or activation of PIM kinases in various cancers follow an isoform-specific pattern. While PIM1 is predominantly expressed in hematological and solid tumors, PIM2 and PIM3 are largely expressed in leukemia and solid tumors, respectively. All of PIM kinases cause transcriptional activation of genes involved in cell survival and cell cycle progression in cancer. A variety of pro-tumorigenic signaling molecules, such as MYC, p21/p27, CDC25, Notch1 and BAD have been identified as the downstream targets of PIM kinases. So far, three kinds of adenosine triphosphate-competitive PIM inhibitors, SGI-1776, AZD1208, and LGH447 have been in clinical trials for the treatment of acute myelogenous leukemia, prostate cancer, lymphoma, or multiple myeloma. This review sheds light on the signaling pathways involved in the PIM kinase regulation and current status of developing PIM kinase inhibitors as clinical success in combating human cancer.

Citing Articles

: Pharmacological potential revealed by phytochemical and in silico investigations.

Naji Bin-Asal F, Saeed A, Alawi Bin Yahia A Biochem Biophys Rep. 2025; 41:101940.

PMID: 39995632 PMC: 11848803. DOI: 10.1016/j.bbrep.2025.101940.

Synthesis of novel pyridine and pyrazolyl pyridine conjugates with potent cytotoxicity against HepG2 cancer cells as PIM-1 kinase inhibitors and caspase activators.

Nafie M, Hamza A, Moustafa A, El-Sayed H, El Rayes S, Morsy H RSC Adv. 2024; 14(53):39381-39394.

PMID: 39679418 PMC: 11638703. DOI: 10.1039/d4ra07963a.

A multitask interpretable model with graph attention mechanism for activity prediction of low-data PIM inhibitors.

Wang Z, Sun L, Chang Y, Yang F, Jiang K Mol Divers. 2024; .

PMID: 39614954 DOI: 10.1007/s11030-024-11060-y.

PIM1 kinase and its diverse substrate in solid tumors.

Choudhury R, Bahadi C, Ray I, Dash P, Pattanaik I, Mishra S Cell Commun Signal. 2024; 22(1):529.

PMID: 39487435 PMC: 11531143. DOI: 10.1186/s12964-024-01898-y.

In silico design and ADMET evaluation of new inhibitors for PIM1 kinase using QSAR studies, molecular docking, and molecular dynamic simulation.

Golestanifar F, Garkani-Nejad Z Heliyon. 2024; 10(19):e38309.

PMID: 39397962 PMC: 11467636. DOI: 10.1016/j.heliyon.2024.e38309.

References

Yang E, Zha J, Jockel J, Boise L, Thompson C, Korsmeyer S . Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995; 80(2):285-91. DOI: 10.1016/0092-8674(95)90411-5. View

Keane N, Reidy M, Natoni A, Raab M, ODwyer M . Targeting the Pim kinases in multiple myeloma. Blood Cancer J. 2015; 5:e325. PMC: 4526774. DOI: 10.1038/bcj.2015.46. View

Zhang Y, Wang Z, Li X, Magnuson N . Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 2008; 27(35):4809-19. DOI: 10.1038/onc.2008.123. View

Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen P, Julkunen I . Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood. 1999; 93(6):1980-91. View

Holder S, Abdulkadir S . PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance. Curr Cancer Drug Targets. 2013; 14(2):105-14. DOI: 10.2174/1568009613666131126113854. View

Kim D, Sung J, Shin E, Ryu J, Choi I, Park K . Association of single nucleotide polymorphisms in PIM-1 gene with the risk of Korean lung cancer. Cancer Res Treat. 2009; 40(4):190-6. PMC: 2697471. DOI: 10.4143/crt.2008.40.4.190. View

Shirogane T, Fukada T, Muller J, Shima D, Hibi M, Hirano T . Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity. 2000; 11(6):709-19. DOI: 10.1016/s1074-7613(00)80145-4. View

Mary Photini S, Chaiwangyen W, Weber M, Al-Kawlani B, Favaro R, Jeschke U . PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells. Exp Cell Res. 2017; 359(1):275-283. DOI: 10.1016/j.yexcr.2017.07.019. View

Liu K, Gao H, Wang Q, Wang L, Zhang B, Han Z . Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer. Cancer Sci. 2018; 109(5):1369-1381. PMC: 5980372. DOI: 10.1111/cas.13575. View

10.

Jessus C, Ozon R . Function and regulation of cdc25 protein phosphate through mitosis and meiosis. Prog Cell Cycle Res. 1995; 1:215-28. DOI: 10.1007/978-1-4615-1809-9_17. View

11.

Santio N, Eerola S, Paatero I, Yli-Kauhaluoma J, Anizon F, Moreau P . Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts. PLoS One. 2015; 10(6):e0130340. PMC: 4467846. DOI: 10.1371/journal.pone.0130340. View

12.

Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S . The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015; 6(35):37930-47. PMC: 4741975. DOI: 10.18632/oncotarget.6122. View

13.

Szydlowski M, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Derezinska E, Hoser G, Wasilewska D . Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood. 2017; 130(12):1418-1429. DOI: 10.1182/blood-2017-01-760702. View

14.

Gao H, Wang H, Peng J . Hispidulin induces apoptosis through mitochondrial dysfunction and inhibition of P13k/Akt signalling pathway in HepG2 cancer cells. Cell Biochem Biophys. 2013; 69(1):27-34. DOI: 10.1007/s12013-013-9762-x. View

15.

Lou L, Wang Y, Cui J, Yan X, Xue L, Li Y . Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach. Tumour Biol. 2014; 35(5):5029-36. DOI: 10.1007/s13277-014-1664-z. View

16.

Kreuz S, Holmes K, Tooze R, Lefevre P . Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Mol Cancer. 2015; 14:205. PMC: 4672512. DOI: 10.1186/s12943-015-0477-z. View

17.

Ma J, Arnold H, Lilly M, Sears R, Kraft A . Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene. 2007; 26(35):5145-53. DOI: 10.1038/sj.onc.1210323. View

18.

Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H . Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent. Bioorg Med Chem Lett. 2015; 25(24):5687-93. DOI: 10.1016/j.bmcl.2015.10.098. View

19.

Jimenez-Garcia M, Lucena-Cacace A, Robles-Frias M, Narlik-Grassow M, Blanco-Aparicio C, Carnero A . The role of PIM1/PIM2 kinases in tumors of the male reproductive system. Sci Rep. 2016; 6:38079. PMC: 5128923. DOI: 10.1038/srep38079. View

20.

Zhou X, Liu Y, Payne G, Lutz R, Chittenden T . Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem. 2000; 275(32):25046-51. DOI: 10.1074/jbc.M002526200. View